Compare Home Depot Inc (HD) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Moderna, Inc. — how do they compare? Home Depot Inc trades at $293.27 (market cap $294.79B), while Moderna, Inc. trades at $205.93 (market cap $78.65B). The key difference: Home Depot Inc is far larger — about 3.7× Moderna, Inc.'s market cap, and Home Depot Inc pays a 3.15% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Moderna, Inc. for 59 Days on average.
| HD | MRNA | |
|---|---|---|
Market Cap | $294.79B | $78.65B |
Volume | 8,693,917 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $203.46 |
52-Week Low | $281.15 | $22.36 |
Typical Hold Time | 139 Days | 59 Days |
Enterprise Value | $355.27B | $74.80B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $285.77, down 0.32% on the day, with a bearish technical signal despite strong analyst support. The stock shows consistent earnings beats in recent quarters with Q2 2026 EPS of $4.92 exceeding expectations. Revenue reached $159.51B in 2025, though profit margins have declined from 10.87% in 2022 to 9.28% currently. Institutional activity shows mixed positioning with some funds increasing while others reducing holdings.
The stock presents a compelling value opportunity with a consensus price target of $379.93 representing 33% upside potential. However, weakening profit margins, rising mortgage rates impacting housing demand, and bearish technical indicators create near-term headwinds. Long-term prospects remain supported by professional segment growth and housing market tailwinds.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
